ClinicalTrials.gg
CompletedNCT01646073Updated Jan 19, 2015Results posted

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

A Phase 3 interventional study of Adalimumab and placebo in Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-19.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
425
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
8th of 48
425 · median 148
Started
2012
with 3 others
Phase 3
26 of 48
1 open now
Registered
23rd of 48
by date
Lead sponsor
6 of 48
AbbVie (prior sponsor, Abbott)

Among the 48 studies testing adalimumab in Psoriasis, this one is the 8th largest by enrollment, is one of 4 that started in 2012, is one of 26 in phase 3, and was the 23rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.

Read the detailed description

The purpose of this study is to evaluate the safety and efficacy of adalimumab and to determine how well it works in the treatment of adults with moderate to severe plaque psoriasis in the Chinese population. Psoriasis is a chronic immunologic disease characterized by marked inflammation and thickening of the epidermis that result in thick, scaly plaques involving the skin.

03

Conditions studied

  • Plaque Psoriasis

Keywords

  • Plaque Psoriasis
  • Psoriasis
  • Placebo Controlled
  • Skin Disease
  • Double Blind
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of psoriasis for at least 6 months.
  • Must have stable plaque psoriasis for at least 2 months before screening and baseline visits.
  • Participant must have a Psoriasis Area Severity Index score greater than or equal to 10 at the baseline visit.
  • Participant must have moderate to severe plaque Psoriasis, defined by Body Surface Area involvement greater than or equal to 10% at the baseline visit.
  • Participant must have a Physicians Global Assessment of at least moderate disease at baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other active skin diseases or skin infections.
  • Participant has known to adalimumab or it .
  • Participant has chronic recurring infections or active tuberculosis.
  • Participant has demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.
  • Participant is known to have immune deficiency or is .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
425 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Adalimumab 40 mg every other week (eow)

    Biological: Adalimumab

  • Placebo comparator
    Placebo

    placebo

    Biological: placebo

Interventions

  • BiologicalAdalimumab

    adalimumab eow

    Also known as: ABT-D2E7, Humira

  • Biologicalplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12

    The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score at Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period A]

    The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI), other than Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

    Time frame: Weeks 3 and 7

  2. Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period B]

    The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

    Time frame: Weeks 16, 19, and 24

  3. Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period A]

    Psoriasis Area and Severity Index (PASI), is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

    Time frame: Baseline to Week 12

  4. Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period B]

    PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

    Time frame: Baseline to Week 24

  5. Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period A]

    The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

    Time frame: Weeks 3, 7, and 12

  6. Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period B]

    The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

    Time frame: Weeks 16, 19, and 24

  7. Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" [Period A]

    The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'

    Time frame: Baseline and Weeks 3, 7, and 12

  8. Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" [Period B]

    The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'

    Time frame: Weeks 16, 19, and 24

  9. Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" or "Minimal" [Period A]

    The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'

    Time frame: Baseline and Weeks 3, 7, and 12

  10. Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" or "Minimal" [Period B]

    The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'

    Time frame: Weeks 16, 19, and 24

  11. Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0" [Period A]

    The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.

    Time frame: Baseline, Week 3, and Week 12

  12. Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0" [Period B]

    The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.

    Time frame: Week 16 and Week 24

  13. Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0 or 1" [Period A]

    The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.

    Time frame: Baseline, Week 3, and Week 12

  14. Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0 or 1" [Period B]

    The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.

    Time frame: Week 16 and Week 24

  15. Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period A]

    Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.

    Time frame: Baseline to Week 12

  16. Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period B]

    Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.

    Time frame: Baseline to Week 24

07

Results

Posted Jan 19, 2015

Participant flow

Period A (12 Weeks)
Participant flow — Period A (12 Weeks)
MilestonePlaceboAdalimumab Eow
Started87338
Completed85333
Not completed25
Withdrew: Adverse event02
Withdrew: Withdrawal by subject11
Withdrew: Lack of efficacy10
Withdrew: Protocol violation01
Withdrew: Other01
Period B (12 Weeks)
Participant flow — Period B (12 Weeks)
MilestonePlaceboAdalimumab Eow
Started85333
Completed84320
Not completed113
Withdrew: Adverse event07
Withdrew: Withdrawal by subject15
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12

The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score at Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12
percentage of participantsPlaceboAdalimumab Eow
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 1211.577.8
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period A]

The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI), other than Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

Time frame:
Weeks 3 and 7
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period A]
percentage of participantsPlaceboAdalimumab Eow
Week 309.8
Week 72.345.3
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period B]

The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

Time frame:
Weeks 16, 19, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period B]
percentage of participantsPlacebo/Adalimumab EowAdalimumab Eow/Adalimumab Eow
Week 1651.887.4
Week 1980.087.1
Week 2490.687.7
SecondaryPercent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period A]

Psoriasis Area and Severity Index (PASI), is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

Time frame:
Baseline to Week 12
Reported as:
Mean · Percent change
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period A]
Percent changePlaceboAdalimumab Eow
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period A]-20.44 ± 3.049-82.20 ± 1.548
SecondaryPercent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period B]

PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period B]
percent changePlacebo/Adalimumab EowAdalimumab Eow/Adalimumab Eow
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period B]-91.39 ± 14.423-91.07 ± 19.028
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period A]

The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

Time frame:
Weeks 3, 7, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period A]
percentage of participantsPlaceboAdalimumab Eow
PASI 50 [Week 3]1.131.7
PASI 90 [Week 3]02.7
PASI 100 [Week 3]00
PASI 50 [Week 7]11.577.2
PASI 90 [Week 7]023.4
PASI 100 [Week 7]03.8
PASI 50 [Week 12]23.088.8
PASI 90 [Week 12]3.455.6
PASI 100 [Week 12]1.113.3
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period B]

The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.

Time frame:
Weeks 16, 19, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period B]
percentage of participantsPlacebo/Adalimumab EowAdalimumab Eow/Adalimumab Eow
PASI 50 [Week 16]71.893.4
PASI 90 [Week 16]28.270.0
PASI 100 [Week 16]8.220.4
PASI 50 [Week 19]92.994.3
PASI 90 [Week 19]56.574.2
PASI 100 [Week 19]22.428.8
PASI 50 [Week 24]94.191.9
PASI 90 [Week 24]75.376.3
PASI 100 [Week 24]34.135.7
SecondaryPercentage of Participants With a Physician's Global Assessment (PGA) of "Clear" [Period A]

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'

Time frame:
Baseline and Weeks 3, 7, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" [Period A]
percentage of participantsPlaceboAdalimumab Eow
Baseline00
Week 300.6
Week 7012.1
Week 121.125.7
SecondaryPercentage of Participants With a Physician's Global Assessment (PGA) of "Clear" [Period B]

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'

Time frame:
Weeks 16, 19, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" [Period B]
percentage of participantsPlacebo/Adalimumab EowAdalimumab Eow/Adalimumab Eow
Week 1614.139.3
Week 1929.442.9
Week 2441.245.6
SecondaryPercentage of Participants With a Physician's Global Assessment (PGA) of "Clear" or "Minimal" [Period A]

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'

Time frame:
Baseline and Weeks 3, 7, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" or "Minimal" [Period A]
percentage of participantsPlaceboAdalimumab Eow
Baseline00
Week 3020.1
Week 74.657.4
Week 1214.980.5
SecondaryPercentage of Participants With a Physician's Global Assessment (PGA) of "Clear" or "Minimal" [Period B]

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'

Time frame:
Weeks 16, 19, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" or "Minimal" [Period B]
percentage of participantsPlacebo/Adalimumab EowAdalimumab Eow/Adalimumab Eow
Week 1661.285.6
Week 1984.784.4
Week 2489.483.8
SecondaryPercentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0" [Period A]

The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.

Time frame:
Baseline, Week 3, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0" [Period A]
percentage of participantsPlaceboAdalimumab Eow
Baseline00.9
Week 31.13.3
Week 12013.0
SecondaryPercentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0" [Period B]

The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.

Time frame:
Week 16 and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0" [Period B]
percentage of participantsPlacebo/Adalimumab EowAdalimumab Eow/Adalimumab Eow
Week 1612.915.0
Week 2423.519.5
SecondaryPercentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0 or 1" [Period A]

The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.

Time frame:
Baseline, Week 3, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0 or 1" [Period A]
percentage of participantsPlaceboAdalimumab Eow
Baseline1.12.4
Week 33.49.2
Week 1210.328.4
SecondaryPercentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0 or 1" [Period B]

The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.

Time frame:
Week 16 and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0 or 1" [Period B]
percentage of participantsPlacebo/Adalimumab EowAdalimumab Eow/Adalimumab Eow
Week 1627.130.0
Week 2444.737.8
SecondaryChange From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period A]

Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.

Time frame:
Baseline to Week 12
Reported as:
Mean · scores on a scale
Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period A]
scores on a scalePlaceboAdalimumab Eow
Physical Component Summary1.13 ± 0.6654.22 ± 0.332
Mental Component Summary1.91 ± 0.9137.02 ± 0.456
SecondaryChange From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period B]

Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.

Time frame:
Baseline to Week 24
Reported as:
Mean · scores on a scale
Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period B]
scores on a scalePlacebo/Adalimumab EowAdalimumab Eow/Adalimumab Eow
Physical Component Summary4.20 ± 8.3514.73 ± 8.260
Mental Component Summary5.74 ± 12.6617.76 ± 11.652

Adverse events

Collected over Baseline up to 70 days after last dose (week 24).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Placebo—3/87 (3.4%)14/87 (16.1%)
Double-blind Adalimumab Eow—4/338 (1.2%)64/338 (18.9%)
Any Adalimumab—15/423 (3.5%)137/423 (32.4%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventDouble-blind PlaceboDouble-blind Adalimumab EowAny Adalimumab
RETINAL DETACHMENTEye disorders1/870/3380/423
PSORIATIC ARTHROPATHYMusculoskeletal and connective tissue disorders1/870/3380/423
PSORIASISSkin and subcutaneous tissue disorders1/870/3380/423
LUNG INFECTIONInfections and infestations0/870/3382/423
PNEUMONIAInfections and infestations0/870/3382/423
MYOCARDIAL INFARCTIONCardiac disorders0/871/3381/423
LUMBAR VERTEBRAL FRACTUREInjury, poisoning and procedural complications0/871/3381/423
CEREBRAL INFARCTIONNervous system disorders0/871/3381/423
HAEMATURIARenal and urinary disorders0/871/3381/423
HYPERTENSIONVascular disorders0/871/3381/423
Most frequent other events
Most frequent other events
EventDouble-blind PlaceboDouble-blind Adalimumab EowAny Adalimumab
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations6/8734/33868/423
NASOPHARYNGITISInfections and infestations5/8713/33838/423
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders1/8714/33830/423
COUGHRespiratory, thoracic and mediastinal disorders4/8711/33827/423

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAdalimumab EowTotal
Mean43.8 ± 12.4543.1 ± 11.9143.2 ± 12.01
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumab EowTotal
Female2984113
Male58254312
Duration of Psoriasis
Duration of Psoriasis(years)PlaceboAdalimumab EowTotal
Mean15.79 ± 10.30914.84 ± 10.11415.03 ± 10.149
Body Surface Area with Psoriasis
Body Surface Area with Psoriasis(Percentage of Body Surface Area)PlaceboAdalimumab EowTotal
Mean39.30 ± 22.50242.62 ± 21.74841.94 ± 21.918
Psoriasis Area and Severity Index
Psoriasis Area and Severity Index(units on a scale)PlaceboAdalimumab EowTotal
Mean25.60 ± 10.97828.19 ± 11.99927.66 ± 11.831
Physician's Global Assessment of Psoriasis
Physician's Global Assessment of Psoriasis(participants)PlaceboAdalimumab EowTotal
Clear000
Minimal000
Mild000
Moderate57214271
Marked28110138
Severe21416
08

Study locations

16 sites
  • Site Reference ID/Investigator# 72888
    Beijing, 100034, China
  • Site Reference ID/Investigator# 72873
    Beijing, 100044, China
  • Site Reference ID/Investigator# 72887
    Beijing, 100730, China
  • Site Reference ID/Investigator# 85693
    Chengdu, 610072, China
  • Site Reference ID/Investigator# 72976
    Chongqing, 400038, China
  • Site Reference ID/Investigator# 72880
    Dalian, 116011, China
  • Site Reference ID/Investigator# 72973
    Guangzhou, 510120, China
  • Site Reference ID/Investigator# 72974
    Guangzhou, 510630, China
  • Site Reference ID/Investigator# 72878
    Hangzhou, Zhejiang, 310003, China
  • Site Reference ID/Investigator# 72877
    Hangzhou, Zhejiang, 310009, China
  • Site Reference ID/Investigator# 87058
    Jinan, 250012, China
  • Site Reference ID/Investigator# 72876
    Shanghai, 200025, China
  • Site Reference ID/Investigator# 72875
    Shanghai, 200433, China
  • Site Reference ID/Investigator# 72883
    Shenyang, 110001, China
  • Site Reference ID/Investigator# 72977
    Wuhan, Hubei, 430022, China
  • Site Reference ID/Investigator# 72975
    Xi'an, 710032, China
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2012
First posted
Jul 20, 2012
Start
Aug 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Jan 19, 2015
Last update
Jan 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01646073
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
Aug 2012
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Jan 19, 2015
Last update
Jan 19, 2015

Study contacts

Martin Okun, MD
study chair · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion